Moderators:
Lars Peters: lars.peters@regionh.dk
Jürgen Rockstroh: juergen.rockstroh@ukb.uni-bonn.de

About:
Co-infection with hepatitis B (HBV) or C (HCV) remain common and clinically important among people with HIV.
Although effective therapy is now available for both HBV and HCV, its use and long-term clinical outcome in a diverse real-life setting are still not well described.

Goals:
To study the long-term effect of HBV and HCV therapy and other factors on the development of hepatic and extra-hepatic morbidity and mortality in HIV/viral hepatitis co-infected persons enrolled in RESPOND

Tasks:
In the RESPOND Hepatitis Scientific Interest Group, clinicians and biostatisticians will develop and execute specific hepatitis research projects to address relevant questions in HIV/viral hepatitis co-infection research

Participants: 
Pontus Hedberg
Colette Smit
Mario Sarcletti
Gilles Wandeler
Philipp de Leuw
Stéphane De Wit
Cristina Mussini
Massimo Puoti
Antonella d'Armininio Monforte
Jose M. Miro
Christoph Boesecke
Jan-Christian Warsmuth
Josep M. Llibre
Roxana Radoi
Cristiana Oprea
Karine Lacombe
Yasmine Abi Aad
Raimonda Matulionyte
Fernndo Maltez
Velida Mulabdic
Vesna Hadziosmanovic
Elena Kuzovatova
Nocola Coppola
Inka Aho
Salvatore Martini
Arjan Harxhi
Robert Zangerle
Dag-Henrik Reikvam
Charles Béguelin
Elżbieta Jablonowska
Erika Duffell 
Sanjay Bhagani
Patrick Ingiliz
Clifford Leen
Milosz Parczewski
Jeffrey Lazarus
Anders Boyd
Luís Mendão
Linda Chen
Michael Mertens
Vani Vannappagari
Amanda Mocroft

CHIP, Copenhagen:
Bastian Neesgaard
Nadine Josephine Jaschinki
Olga Fursa